INmune Bio (INMB) IPO Opens at $8.44
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
INmune Bio Inc. Announces Closing of Initial Public Offering and Trading on the Nasdaq Capital Market Under the Ticker Symbol “INMB”
February 4, 2019 8:55 AM ESTLA JOLLA, CA, Feb. 04, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (INmune or the Company), an immunotherapy company focused on developing therapies that harness the patients innate immune system to fight disease, today announced that the Companys common stock is expected to commence trading on The Nasdaq Capital Market, on Monday, February 4, 2019 under the ticker symbol INMB.
On February 1, 2019, INmune closed its initial public offering (IPO) of 1,020,560 shares of its common stock at of $8.00 per share for a total of $8,166,560 in gross proceeds before placement agent fees and offering expenses.
Univest Securities, LLC... More
INmune Bio Inc. Announces Closing of Initial Public Offering and Trading on the Nasdaq Capital Market Under the Ticker Symbol “INMB”
February 4, 2019 8:55 AM ESTLA JOLLA, CA, Feb. 04, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (INmune or the Company), an immunotherapy company focused on developing therapies that harness the patients innate immune system to fight disease, today announced that the Companys common stock is expected to commence trading on The Nasdaq Capital Market, on Monday, February 4, 2019 under the ticker symbol INMB.
On February 1, 2019, INmune closed its initial public offering (IPO) of 1,020,560 shares of its common stock at of $8.00 per share for a total of $8,166,560 in gross proceeds before placement agent fees and offering expenses.
Univest... More
